NCT06643000View on ClinicalTrials.gov

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

March 30, 2025

Study Completion Date

May 30, 2025

Conditions
Non-small Cell Lung CancerLeptomeningeal MetastasisEGFR Gene Mutation
Interventions
DRUG

furmonertinib

furmonertinib (240 mg/d,po) combined with bevacizumab (15 mg/kg, every 3 weeks, ivgtt) and pemetrexed (50 mg) intrathecal chemotherapy / pemetrexed (500 mg/m²) intravenous chemotherapy, administered every 3 weeks.

Trial Locations (2)

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

Unknown

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV